These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9625466)
1. Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies. Marr K; Marsh K; Hernandez L; Cunningham FM; Lees P Res Vet Sci; 1998; 64(2):111-7. PubMed ID: 9625466 [TBL] [Abstract][Full Text] [Related]
2. Effect of the 5-lipoxygenase inhibitor, fenleuton, on antigen-induced neutrophil accumulation and lung function changes in horses with chronic obstructive pulmonary disease. Marr KA; Lees P; Page CP; Cunningham FM J Vet Pharmacol Ther; 1998 Jun; 21(3):241-6. PubMed ID: 9673966 [TBL] [Abstract][Full Text] [Related]
3. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. Cunningham FM; Andrews M; Landoni MF; Lees P J Vet Pharmacol Ther; 1997 Aug; 20(4):296-307. PubMed ID: 9280370 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of leukotriene B4 biosynthesis by disulfiram and A-64077 during carrageenan-induced pleurisy in the rat. Riendeau D; Guay J; Foster A; Wolfe S; Chan CC Gen Pharmacol; 1991; 22(2):371-4. PubMed ID: 1647348 [TBL] [Abstract][Full Text] [Related]
7. Effect of 5-lipoxygenase inhibitors on in situ LTB4 biosynthesis following calcium ionophore stimulation in the rat pleural cavity. Raychaudhuri A; Chertock H; Peppard J; White WD; Koeler J; DiPasquale G Agents Actions; 1993; 39 Spec No():C43-5. PubMed ID: 8273581 [TBL] [Abstract][Full Text] [Related]
8. 5-lipoxygenase inhibitory activity of zileuton. Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. Landoni MF; Lees P Equine Vet J; 1995 Jul; 27(4):247-56. PubMed ID: 8536660 [TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577 [TBL] [Abstract][Full Text] [Related]
12. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186 [TBL] [Abstract][Full Text] [Related]
13. A-78773: a selective, potent 5-lipoxygenase inhibitor. Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248 [TBL] [Abstract][Full Text] [Related]
14. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. Bell RL; Bouska J; Young PR; Lanni C; Machinist J; Malo PE; Summers JB; Brooks DW; Carter GW Agents Actions; 1993 Mar; 38(3-4):178-87. PubMed ID: 8213344 [TBL] [Abstract][Full Text] [Related]
15. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase. Kimble E; Kowalski T; White D; Raychauduri A; Pastor G; Chertock H; Lee W; Neale R; Hamdan A; Wasley J Agents Actions; 1991 Sep; 34(1-2):125-8. PubMed ID: 1665286 [TBL] [Abstract][Full Text] [Related]
16. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271 [TBL] [Abstract][Full Text] [Related]
17. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Horizoe T; Nagakura N; Chiba K; Shirota H; Shinoda M; Kobayashi N; Numata H; Okamoto Y; Kobayashi S Inflamm Res; 1998 Oct; 47(10):375-83. PubMed ID: 9831321 [TBL] [Abstract][Full Text] [Related]
18. Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo. Sirois P; Borgeat P; Lauzière M; Dubé L; Rubin P; Kesterson J Agents Actions; 1991 Sep; 34(1-2):117-20. PubMed ID: 1665285 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379 [TBL] [Abstract][Full Text] [Related]
20. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. Crawley GC; Dowell RI; Edwards PN; Foster SJ; McMillan RM; Walker ER; Waterson D; Bird TG; Bruneau P; Giroaeau JM J Med Chem; 1992 Jul; 35(14):2600-9. PubMed ID: 1321908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]